PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.32%
Both companies show declining cash positions (-7.32% vs AGEN's -9.71%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.32%
Cash + STI yoy 0.75-0.9x AGEN's -9.71%. Bill Ackman would wonder if competitor is building liquidity more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.49%
Similar to AGEN's -53.22%. Walter Schloss would confirm standard short-term asset patterns.
-6.31%
0.5-0.75x AGEN's -9.13%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-8.93%
≥ 1.5x AGEN's -5.22%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.62%
Less than half of AGEN's 39.97%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-7.75%
≥ 1.5x AGEN's -4.05%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
1.25-1.5x AGEN's -5.12%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.18%
Less than half of AGEN's -45.78%. David Dodd sees fewer expansions in other current obligations.
5.07%
Less than half of AGEN's -18.19%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.44%
Less than half of AGEN's 29.90%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
0.54%
Less than half of AGEN's 4.39%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.80%
0.75-0.9x AGEN's -2.15%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.26%
Below half AGEN's -273.75%. Michael Burry sees potential underperformance in building shareholder capital.
-6.35%
1.25-1.5x AGEN's -5.12%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
-8.07%
Less than half of AGEN's 71.98%. David Dodd sees less overall debt expansion vs. competitor.
7.30%
Less than half of AGEN's 424.40%. David Dodd sees better deleveraging or stronger cash buildup than competitor.